^
Association details:
| Biomarker: | GOPC-ROS1 fusion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Published date:
01/07/2021
Excerpt:
We identified all cases with RTK fusions in patients with colorectal cancer...The second patient, whose tumor contained an ROS1-GOPC fusion, continues to benefit from entrectinib after 9 months of therapy.
DOI:
10.1158/1078-0432.CCR-20-4073
